Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor: Avidity Biosciences, Inc.
Summary
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Official title: A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Key Details
Gender
All
Age Range
16 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2024-07-25
Completion Date
2028-04
Last Updated
2024-12-20
Healthy Volunteers
No
Conditions
Interventions
AOC 1020
AOC 1020 will be administered via intravenous (IV) infusion
Locations (17)
University of California Los Angeles
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of California San Diego
San Diego, California, United States
University of Colorado
Denver, Colorado, United States
University of Florida
Gainesville, Florida, United States
Rare Disease Research
Atlanta, Georgia, United States
Kansas University Medical Center
Kansas City, Kansas, United States
University of Rochester Medical Center
Rochester, New York, United States
Duke University
Durham, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Texas Southwestern
Dallas, Texas, United States
Virginia Commonwealth University
Richmond, Virginia, United States
University of Washington
Seattle, Washington, United States
University of Ottawa
Ottawa, Ontario, Canada
University College London
London, United Kingdom
University of Sheffield
Sheffield, United Kingdom